Verbal Intent and Gaze Cues on Action Prediction in ASD

Exploration of Verbal Intention and Gaze Clues Characteristics in Children With Autism: Based on Eye Tracking Technology

A 2×2×3 mixed design (intent word × object type × group: TD, ASD, ID) was used. Age-matched children watched videos and judged which object a model would pick; their choices and eye movements were recorded.

Study Overview

Detailed Description

A 2 (intent word: like, dislike) × 2 (object type: mentioned, unmentioned) × 3 (participant group: ASD, TD, ID) mixed experimental design was adopted. Children from the three age-matched groups (29 TD, 22 ASD, 24 ID) completed a video-watching task. In the video, a model was presented with two objects and uttered a sentence containing an intent word, a verb, and a noun, such as "I like to eat oranges." Based on the intent word, trials were divided into "like" and "dislike" conditions. Objects were classified as "mentioned" or "unmentioned" according to the verb and noun used. Participants were required to judge which object the model would pick while watching the video. Their choice responses and eye movements were recorded.

Study Type

Observational

Enrollment (Actual)

80

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Sichuan
      • Chengdu, Sichuan, China, 611731
        • School of Foreign Languages, University of Electronic Science and Technology of China

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

A total of 80 children (aged 3-10 years) were initially recruited and divided into three groups: 29 typically developing (TD) children (25 boys, 4 girls) from a kindergarten or primary school in Sichuan Province; 26 children with autism spectrum disorder (ASD) (20 boys, 6 girls) from a local disability federation or autism rehabilitation center in Chengdu, Sichuan Province, all clinically diagnosed and assessed with the Autism Diagnostic Observation Schedule (ADOS); and 25 children with intellectual disability (ID) (14 boys, 11 girls) from a disability federation or rehabilitation center in Chengdu, Sichuan Province, all clinically diagnosed. Based on eye-tracking data, 4 ASD participants and 1 ID participant whose total fixation duration accounted for less than 50% of the total trial time were excluded. Consequently, the final sample included 29 TD children (25 boys, 4 girls), 22 ASD children (18 boys, 4 girls), and 24 ID children (13 boys, 11 girls) for data analysis.

Description

Inclusion Criteria:

- Children clinically diagnosed with Autism Spectrum Disorder (ASD). Typically developing (TD) children with no developmental or neurological disorders.

Children clinically diagnosed with Intellectual Disability (ID).

Common criteria for all groups: Normal or corrected-to-normal vision, no color vision deficiencies, normal hearing, and written informed consent provided by their legal guardians.

Exclusion Criteria:

- Failure to meet the study's group-specific screening cutoffs on the Social Responsiveness Scale (SRS) and Social Communication Questionnaire (SCQ).

Failure to meet the study's group-specific screening cutoffs on the Autism Diagnostic Observation Schedule (ADOS).

Known genetic syndromes, significant hearing loss, or uncorrectable visual impairment.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Autism Spectrum Disorder (ASD) Group
Typically Developing (TD) Group
Intellectual Disability(ID)Group

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of Total Fixation Duration on Objects
Time Frame: During the full 13 seconds video presentation
Percentage of Total Fixation Duration on Objects = (Total time fixating on target objects ÷ Total fixation duration across the scene) × 100%. It measures how much of overall viewing time is spent attending to predefined objects, reflecting attentional priority and object-driven cognitive engagement, normalized for individual differences.
During the full 13 seconds video presentation
The time to first fixation on an object within each defined TOI (Time of Interest)
Time Frame: During the 0-2 s, 2-6 s, and 6-8 s intervals of video
Time to First Fixation on an Object within a TOI = time elapsed from TOI onset until the first fixation lands on that object. It measures how quickly attention is drawn to a target, reflecting salience or search efficiency. Shorter times indicate faster capture.
During the 0-2 s, 2-6 s, and 6-8 s intervals of video

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 15, 2025

Primary Completion (Actual)

January 29, 2026

Study Completion (Actual)

March 27, 2026

Study Registration Dates

First Submitted

May 6, 2026

First Submitted That Met QC Criteria

May 13, 2026

First Posted (Actual)

May 19, 2026

Study Record Updates

Last Update Posted (Actual)

May 19, 2026

Last Update Submitted That Met QC Criteria

May 13, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Intellectual Disability

Subscribe